Dr. Barbara Papadopoulou, B.Pharm., M.Sc., Ph.D., is a Professor in the Department of Microbiology-Infectious Disease and Immunology of the Laval University School of Medicine and the Director of the Axis of Infectious Diseases and Immunity of the CHU de Quebec Research Center-Laval University, since 2010. Her areas of expertise are parasitic diseases, regulation of gene expression, microbial pathogenesis, genomics, and vaccinology. Over the years, her laboratory has made remarkable discoveries on the molecular mechanisms controlling the intracellular development of the protozoan parasite Leishmania and on post-transcriptional regulation by novel classes of 3’UTR elements and RNA binding factors that have significantly advanced knowledge in this area. The fascinating concept of coordinated gene regulation by retroposons has revolutionized the landscape of gene expression control in this parasite. Her laboratory has also been a pioneer in the use of reverse genetics and genomics in Leishmania. She has also contributed to original work on the development of promising vaccine strategies against Leishmania infections. Her sustained efforts on vaccine development have led to patents and innovative live vaccine-based strategies that are currently being evaluated in relevant disease models in endemic countries. Dr. Papadopoulou is an internationally recognized leader in the field of Leishmania. She currently holds some very influential roles in international research networks (Leishmania Genome Network, TriTrypDB, The European Cooperation in the Field of Scientific and Technical Research COST B22) and in advisory expert committees (WorldLeish, World Health Organization) and she has established numerous collaborations, internationally. She has been actively involved, as member of the organizing scientific or local committees, in the organization of more than 8 international congresses on leishmaniasis and other parasitic diseases, and has also organized more than 15 symposia in this field.

Dr. Papadopoulou is the author of over 135 scientific publications and of several reviews and book chapters. She has received several prestigious national and international awards and distinctions for excellence in research, including the Burroughs Wellcome Fund Award in Molecular Parasitology for her outstanding contributions to the field of Leishmania research, and the nomination as Fellow of the Canadian Academy of Health Sciences, in 2013. Her leadership role as a woman in biomedical sciences has also been highlighted on several occasions (YWCA Women of Distinction Award Winner 2012, Science and Technology, 50 Successful Women from the Quebec City Region of Chaudière-Appalaches, ’22 Quebecers to watch’ by L’Actualité magazine, etc.). Dr. Papadopoulou is a member of several international consortia, as well as national (CIHR) and international (Burroughs Wellcome Fund Pathogenesis of Infectious Disease Program, Faculty of 1000 Biology, National Council for Scientific and Technological Development/Brazil, Hellenic Quality Assurance Agency for higher education, etc.) peer review and advisory committees. She is also an elected Faculty member of Greek Universities (APELLA). Until recently, she was until a member and Vice-Chairman of the Board of Directors of the Fonds de Recherche du Québec-Santé (FRQS) and the Board of Directors of the Canadian Academy of Health Sciences.

CHUL
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

112 entries « 1 of 23 »

Aguiar BG, Padmanabhan PK, Dumas C, Papadopoulou B

Valosin-containing protein VCP/p97 is essential for the intracellular development of Leishmania and its survival under heat stress.

Journal Article

Cell Microbiol, pp. e12867, 2018, ISSN: 1462-5814.

Abstract | Links:

de Melo Neto OP, da Costa Lima TDC, Merlo KC, Romao TP, Rocha PO, Assis LA, Nascimento LM, Xavier CC, Rezende AM, Reis CRS, Papadopoulou B

Phosphorylation and interactions associated with the control of the Leishmania Poly-A Binding Protein 1 (PABP1) function during translation initiation.

Journal Article

RNA Biol, pp. 1-17, 2018, ISSN: 1547-6286.

Abstract | Links:

Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, Lopez-Velez R, Garcia-Hernandez R, Pountain AW, Mwenechanya R, Papadopoulou B

Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.

Journal Article

PLoS Negl Trop Dis, 11 (12), pp. e0006052, 2017, ISSN: 1935-2727.

Abstract | Links:

Azizi H, Muller-McNicoll M, Papadopoulou B

SIDER2 retroposon-mediated mRNA decay in Leishmania is coupled to translation.

Journal Article

Int J Parasitol, 47 (6), pp. 305-310, 2017, ISSN: 0020-7519.

Abstract | Links:

Azizi H, Romao TP, Santos Charret K, Padmanabhan PK, de Melo Neto OP, Muller-McNicoll M, Papadopoulou B

RNA secondary structure and nucleotide composition of the conserved hallmark sequence of Leishmania SIDER2 retroposons are essential for endonucleolytic cleavage and mRNA degradation.

Journal Article

PLoS ONE, 12 (7), pp. e0180678, 2017.

Abstract | Links:

112 entries « 1 of 23 »

Active projects

  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Post-transcriptional regulatory networks coordinating developmental gene expression in the human pathogen Leishmania, Subvention, Instituts de recherche en santé du Canada, Volet Projet: Concours pilotes, from 2016-07-01 to 2021-06-30

Recently finished projects

  • 3.5 Impact of environmental conditions on airway microbiota and resratory health in the North, Subvention, Secrétariat des programmes interorganismes à l’intention des établissements, Fonds d'excellence en recherche Apogée Canada, from 2017-04-01 to 2018-03-31
  • Centre de recherche en infectiologie, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2018-04-30
  • Centre de recherche sur les interactions hôte-parasite (CRIHP), Subvention, Fonds de recherche du Québec - Nature et technologies, Regroupements stratégiques, from 2015-04-01 to 2017-03-31
  • Human and Microbial Integrative Genomics, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds de l'avant-garde (FA), from 2012-09-01 to 2016-08-31
  • Projet de recherche dans l'axe maladies infectieuses et immunitaires., Subvention, Fondation du CHU de Québec, from 2016-04-01 to 2017-03-31
  • The role of eIF2alpha phosphorylation in controlling intracellular development of Leishmania, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2012-04-01 to 2017-03-31
Data provided by the Université Laval research projects registery